Psychedelics clinical trial start-up Clerkenwell Health to sponsor PSYCH Symposium London 2023
London, 04 July 2023 – Clerkenwell Health, a specialist clinical research organisation (CRO) focused on supporting clients with the design and delivery of psychedelic-assisted therapy trials, is pleased to announce its sponsorship of the upcoming PSYCH Symposium 2023 on Thursday 6 July in London.
PSYCH Symposium 2023, hosted by PSYCH, the industry’s premium business-business media platform, is Europe’s flagship event for psychedelic healthcare. The conference will bring together leading figures from policy, science and business, illuminating the societal and investment opportunities created by psychedelic science and will look at global and European policy developments, funding challenges and patient access to explore the intersection of healthcare, policy and psychedelics.
Clerkenwell Health is sponsoring the conference with its co-panellists, PharmAla Biotech, Eramol and Transpharmation Ltd. The panel will focus on the process of psychedelic trials from pre-clinical and manufacturing through to import-export and clinical trials, outlining the complexities that these compounds bring to drug development. Featuring on the panel, George McBride, Chief Commercial Officer and Clare Knight, Senior Clinical Trial Manager at Clerkenwell Health will draw on their own experience from both sides of the Atlantic and within the Commonwealth.
Further PSYCH Symposium 2023 speakers include leading figures such as:
- Professor Robin Carhart-Harris – Head of the Centre for Psychedelic Research, Imperial College London
- Professor Celia Morgan – Head of Ketamine Assisted Psychotherapy for Addiction, Awakn Life Sciences
- Christian Angermayer – Founder, Apeiron Investment Group
- Mikuláš Peksa – MEP, European Parliament
- Dr David Erritzoe – Clinical Senior Lecturer & Consultant Psychiatrist, Imperial College London
- Tadeusz Hawrot – Founder and Executive Director, PAREA
- Charlotte Nichols – Labour, Member of UK Parliament
- Amir Inamdar – Chief Medical Officer, Cybin Inc
Clerkenwell’s participation is announced following its recent news that it has received MHRA approval to run a first-of-its kind trial in London to test whether a novel psilocin prodrug can treat major depressive disorders when combined with therapy. The CRO is now working on designing and delivering several new trials for complex mental health conditions including PTSD, alcohol use disorder, treatment-resistant depression and anxiety and is actively recruiting patients.
To attend the conference, please visit PSYCH Symposium’s website.
To find out more about patient recruitment, visit Clerkenwell Health’s website.
